PubRank

Jane A McKeating

Author PubWeight™ 163.55‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Complete replication of hepatitis C virus in cell culture. Science 2005 18.59
2 Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J Virol 2002 11.99
3 Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 2007 9.52
4 Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc Natl Acad Sci U S A 2003 8.21
5 EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat Med 2011 6.21
6 Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat Med 2007 6.05
7 Efficient replication of hepatitis C virus genotype 1a RNAs in cell culture. J Virol 2003 3.84
8 Time- and temperature-dependent activation of hepatitis C virus for low-pH-triggered entry. J Virol 2006 3.71
9 Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro. Proc Natl Acad Sci U S A 2006 3.69
10 CD81 is required for hepatitis C virus glycoprotein-mediated viral infection. J Virol 2004 3.53
11 Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo. Gastroenterology 2006 3.44
12 Hepatitis C virus glycoproteins interact with DC-SIGN and DC-SIGNR. J Virol 2003 3.10
13 Hepatitis C virus cell-cell transmission in hepatoma cells in the presence of neutralizing antibodies. Hepatology 2008 3.09
14 Persistent hepatitis C virus infection in vitro: coevolution of virus and host. J Virol 2006 2.77
15 Initiation of hepatitis C virus infection is dependent on cholesterol and cooperativity between CD81 and scavenger receptor B type I. J Virol 2006 2.65
16 Hepatitis C virus infects the endothelial cells of the blood-brain barrier. Gastroenterology 2011 2.51
17 Hepatitis C virus receptor expression in normal and diseased liver tissue. Hepatology 2008 2.43
18 Diverse CD81 proteins support hepatitis C virus infection. J Virol 2006 2.07
19 Discordant role of CD4 T-cell response relative to neutralizing antibody and CD8 T-cell responses in acute hepatitis C. Gastroenterology 2006 2.05
20 Oxidized low-density lipoprotein inhibits hepatitis C virus cell entry in human hepatoma cells. Hepatology 2006 2.04
21 Multiple effects of silymarin on the hepatitis C virus lifecycle. Hepatology 2010 1.92
22 Inhibition of hepatitis C virus infection by anti-claudin-1 antibodies is mediated by neutralization of E2-CD81-claudin-1 associations. Hepatology 2010 1.87
23 Superinfection exclusion in cells infected with hepatitis C virus. J Virol 2007 1.71
24 Scavenger receptor BI and BII expression levels modulate hepatitis C virus infectivity. J Virol 2007 1.68
25 Neutralizing antibody-resistant hepatitis C virus cell-to-cell transmission. J Virol 2010 1.67
26 Claudin association with CD81 defines hepatitis C virus entry. J Biol Chem 2010 1.67
27 CD81 and claudin 1 coreceptor association: role in hepatitis C virus entry. J Virol 2008 1.62
28 Monoclonal anti-claudin 1 antibodies prevent hepatitis C virus infection of primary human hepatocytes. Gastroenterology 2010 1.58
29 Identification of a residue in hepatitis C virus E2 glycoprotein that determines scavenger receptor BI and CD81 receptor dependency and sensitivity to neutralizing antibodies. J Virol 2008 1.48
30 Paracrine signals from liver sinusoidal endothelium regulate hepatitis C virus replication. Hepatology 2013 1.47
31 Polarization restricts hepatitis C virus entry into HepG2 hepatoma cells. J Virol 2009 1.44
32 Effect of cell polarization on hepatitis C virus entry. J Virol 2007 1.41
33 Small molecule scavenger receptor BI antagonists are potent HCV entry inhibitors. J Hepatol 2010 1.37
34 HRas signal transduction promotes hepatitis C virus cell entry by triggering assembly of the host tetraspanin receptor complex. Cell Host Microbe 2013 1.37
35 IFITM1 is a tight junction protein that inhibits hepatitis C virus entry. Hepatology 2012 1.36
36 Hepatitis C virus infection of neuroepithelioma cell lines. Gastroenterology 2010 1.35
37 Hepatitis C virus (HCV)-specific immune responses of long-term injection drug users frequently exposed to HCV. J Infect Dis 2008 1.30
38 Hepatitis C virus envelope glycoprotein immunization of rodents elicits cross-reactive neutralizing antibodies. Vaccine 2007 1.28
39 In vitro selection of a neutralization-resistant hepatitis C virus escape mutant. Proc Natl Acad Sci U S A 2008 1.25
40 Characterization of infectious retroviral pseudotype particles bearing hepatitis C virus glycoproteins. J Virol 2004 1.23
41 Hepatitis C virus entry: beyond receptors. Rev Med Virol 2012 1.23
42 Hepatitis C virus infection reduces hepatocellular polarity in a vascular endothelial growth factor-dependent manner. Gastroenterology 2009 1.17
43 Hepatitis C virus induces CD81 and claudin-1 endocytosis. J Virol 2012 1.14
44 Mutations in hepatitis C virus E2 located outside the CD81 binding sites lead to escape from broadly neutralizing antibodies but compromise virus infectivity. J Virol 2009 1.13
45 Naturally occurring antibodies that recognize linear epitopes in the amino terminus of the hepatitis C virus E2 protein confer noninterfering, additive neutralization. J Virol 2011 1.13
46 Protein kinase A-dependent step(s) in hepatitis C virus entry and infectivity. J Virol 2008 1.12
47 Heterogeneous claudin-1 expression in human liver. Hepatology 2013 1.11
48 Development of novel therapies for hepatitis C. Antiviral Res 2010 1.09
49 Hepatitis C virus association with peripheral blood B lymphocytes potentiates viral infection of liver-derived hepatoma cells. Blood 2008 1.05
50 Expression of DC-SIGN and DC-SIGNR on human sinusoidal endothelium: a role for capturing hepatitis C virus particles. Am J Pathol 2006 1.04
51 Hepatoma cell density promotes claudin-1 and scavenger receptor BI expression and hepatitis C virus internalization. J Virol 2009 1.04
52 Hepatitis C virus envelope glycoprotein fitness defines virus population composition following transmission to a new host. J Virol 2012 1.02
53 Hepatitis C virus entry and neutralization. Clin Liver Dis 2008 1.02
54 Pharmacological characterization of the chemokine receptor, CCR5. Br J Pharmacol 2002 1.00
55 A dual role for hypoxia inducible factor-1α in the hepatitis C virus lifecycle and hepatoma migration. J Hepatol 2011 1.00
56 An alpaca nanobody inhibits hepatitis C virus entry and cell-to-cell transmission. Hepatology 2013 0.96
57 Immunization of human volunteers with hepatitis C virus envelope glycoproteins elicits antibodies that cross-neutralize heterologous virus strains. J Infect Dis 2011 0.93
58 Early infection events highlight the limited transmissibility of hepatitis C virus in vitro. J Hepatol 2013 0.90
59 Combined adenovirus vector and hepatitis C virus envelope protein prime-boost regimen elicits T cell and neutralizing antibody immune responses. J Virol 2014 0.90
60 Functional analysis of claudin-6 and claudin-9 as entry factors for hepatitis C virus infection of human hepatocytes by using monoclonal antibodies. J Virol 2013 0.89
61 Activated macrophages promote hepatitis C virus entry in a tumor necrosis factor-dependent manner. Hepatology 2014 0.88
62 Mechanisms of viral entry: sneaking in the front door. Protoplasma 2010 0.88
63 Over the fence or through the gate: how viruses infect polarized cells. Immunotherapy 2012 0.88
64 Polymersome-mediated delivery of combination anticancer therapy to head and neck cancer cells: 2D and 3D in vitro evaluation. Mol Pharm 2014 0.86
65 Hepatitis C virus entry and the tetraspanin CD81. Biochem Soc Trans 2011 0.86
66 Structural characterization of recombinant human CD81 produced in Pichia pastoris. Protein Expr Purif 2007 0.85
67 In silico directed mutagenesis identifies the CD81/claudin-1 hepatitis C virus receptor interface. Cell Microbiol 2012 0.85
68 Hepatitis C virus targets the T cell secretory machinery as a mechanism of immune evasion. Hepatology 2011 0.83
69 The complexities of hepatitis C virus entry. J Hepatol 2009 0.80
70 In vitro veritas? The challenges of studying hepatitis C virus infectivity in a test tube. J Hepatol 2006 0.79
71 Production, purification and characterization of recombinant, full-length human claudin-1. PLoS One 2013 0.78
72 Type I interferon rapidly restricts infectious hepatitis C virus particle genesis. Hepatology 2014 0.77
73 Structural characterization of CD81-Claudin-1 hepatitis C virus receptor complexes. Biochem Soc Trans 2011 0.77
74 A bile acid transporter as a candidate receptor for hepatitis B and D virus entry. J Hepatol 2013 0.77
75 Rituximab treatment in hepatitis C infection: an in vitro model to study the impact of B cell depletion on virus infectivity. PLoS One 2011 0.76
76 Correction to 'Viral hepatitis and liver cancer'. Philos Trans R Soc Lond B Biol Sci 2018 0.75